ophtAI




Artificial Intelligence for Retinal Screening



One picture

One second

One screening



ophtAI

Artificial **I**ntelligence for Retinal Screening

Features

OphtAI is an eye pathology detection service based on retinal photo analysis (45° standard photography).

OphtAI is based on Artificial Intelligence, trained on several hundred thousand images of the retina fully annotated by expert retinologists from OphDiaT network.

- Photo quality assessment
- DR severity assessment
- Detected lesions mapping
- Result predictive value index
- Health Data Host (HDH)
- GDPR

CE, Sante Canada, UKCA Class IIa Medical Device

RDR	Sensitivity: 99% / Specificity: 87%
Diabetic macular edema	Sensitivity: 96.8% / Specificity: 96.3%
Glaucoma	Sensitivity: 92.5% / Specificity: 87%
AMD	Sensitivity: 96,5% / Specificity: 95.4%
Drusen	Sensitivity: 95.3% / Specificity: 94.6%
Upcoming version (2024)	Normal / Abnormal retina Nevus Degenerative myopia Macular hole Epiretinal membrane Central Vein Occlusion Branch Vein Occlusion Retinitis Pigmentosa Maternal Inherited Deafness and Diabetes (MIDD) Laser photocoagulation scar Cataract


Value Proposal

- **OphtAI** is the right tool for **large scale screening**
- **OphtAI** strengthens first-line screening organizations
- **OphtAI** reduces ophthalmologists' workload allowing them to focus on diagnosis and treatment



Commercial offer

- **Monthly subscription**
- **Unlimited use**
- **Cancel anytime**
- **1-month free trial**



Available as **stand-alone zero footprint service** from any web browser




Open an online account
and drop retinal images

my.ophtai.com




Retrieve analysis results in real time



Download the
PDF report

Available as an **integrated service** within your business software

- 1st automatic reading
- File classification by criticality for DR Coordinated care protocols
- Optimizing your working time




Our partners:

TOPCON: Harmony
OPTOMED: Aurora
CrystalVue NFC-700
iCare: Illume

SOLETYS: AREA
Spélogic
Téléophtalmo
OphCare ...

Available as **automated analysis client** for images imported into a directory

OphtAI.service



ophtAI

Artificial Intelligence for Retinal Screening

- **Winner of the 2019 Innovation Award -** French Society for Digital Health
- **Top 10 leading providers of medical AI solutions in Europe** - Healthcare Tech Outlook
- **Winner of the Veterans Affair Contest organized by the University of Washington, Seattle for Diabetic Retinopathy Screening - Best sensitivity** - Diabetes Care

The company

- **2019:** Creation of OphtAI, an affiliate of the French EVOLUCARE Technologies group. A company dedicated to the application of Artificial Intelligence in Ophthalmology.
- **2020:** Creation of a joint-venture with a public/private research laboratory, INSERM.
- **2021:** Involvement in public and private projects for developing AI for new imaging technologies. Health Canada registration
- **2022:** Filing for Compliance to new CE Medical Device Regulation
- **2023:** UKCA Registration

Customer's feedback

"Integrating OphtAI into our practice has become an essential part of our performance and patient safety. We would find it difficult to work without it."

Dr Vincent GUALINO, Honoré Cave Clinic, Montauban (France)
20 months' use of OphtAI integrated into AREA software (Soletys).

Our partners

Financial partners

CE 0459 — ISO 13485:2016 — Health Canada approved / Certifié par Santé Canada

CE and Health Canada Marked Class IIa MD - Not for sale in the U.S.A.

Evolucare Uview/OphtAI is a Class IIa medical device manufactured by Evolucare Technologies (51901881600016). CE 0459. Certification body: GMED. Please read the device user manual carefully before use.

www.ophtai.com
contact@ophtai.com
+33(0)3 22 50 37 90

2310PLOPHTPM001 - RB2 Conseil 2023 - 0608261930